Equity Overview
Price & Market Data
Price: $2.45
Daily Change: -$0.07 / 2.86%
Daily Range: $2.45 - $2.60
Market Cap: $941,159,680
Daily Volume: 1,561
Performance Metrics
1 Week: 23.12%
1 Month: 11.87%
3 Months: 11.36%
6 Months: 4.70%
1 Year: 11.36%
YTD: 2.08%
Details
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.